Component

SGLT2 inhibitor exposure

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. SGLT2 inhibitors may lower serum lithium.

    Experimental context and source evidence
    evidence_access
    Official prescribing information
    experimental_model
    Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06.
    limitations
    Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    Not all renal drug interactions increase exposure.
    primary_references
    Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 592–598

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. · source_derived_draft · unverified_draft

    ## lithium-sglt2-interaction Not all renal drug interactions increase exposure. SGLT2 inhibitors may lower serum lithium. Model: Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. Limitations: Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows. Evidence access: Official prescribing information Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards